These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38847983)

  • 41. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology.
    Pillai S; Gopalan V; Smith RA; Lam AK
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):64-73. PubMed ID: 25577570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study.
    Ding Z; Tao X; Deng X; Guo B; Kang J; Wu B; Yang Z; Chen C; Liu P; Zhang Y; Fan Y; Liu Z
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6303-6313. PubMed ID: 36735028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Follicular cell thyroid neoplasia: insights from genomics and The Cancer Genome Atlas research network.
    Giordano TJ
    Curr Opin Oncol; 2016 Jan; 28(1):1-4. PubMed ID: 26569424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
    Huang Y; Qu S; Zhu G; Wang F; Liu R; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
    J Natl Cancer Inst; 2018 Apr; 110(4):362-370. PubMed ID: 29165667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
    Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
    Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
    Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
    Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
    Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
    [No Abstract]   [Full Text] [Related]  

  • 52. Genomic characterization of cervical lymph node metastases in papillary thyroid carcinoma following the Chornobyl accident.
    Morton LM; Lee OW; Karyadi DM; Bogdanova TI; Stewart C; Hartley SW; Breeze CE; Schonfeld SJ; Cahoon EK; Drozdovitch V; Masiuk S; Chepurny M; Zurnadzhy LY; Dai J; Krznaric M; Yeager M; Hutchinson A; Hicks BD; Dagnall CL; Steinberg MK; Jones K; Jain K; Jordan B; Machiela MJ; Dawson ET; Vij V; Gastier-Foster JM; Bowen J; Mabuchi K; Hatch M; Berrington de Gonzalez A; Getz G; Tronko MD; Thomas GA; Chanock SJ
    Nat Commun; 2024 Jun; 15(1):5053. PubMed ID: 38871684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors.
    Titov SE; Ivanov MK; Karpinskaya EV; Tsivlikova EV; Shevchenko SP; Veryaskina YA; Akhmerova LG; Poloz TL; Klimova OA; Gulyaeva LF; Zhimulev IF; Kolesnikov NN
    BMC Cancer; 2016 Mar; 16():201. PubMed ID: 26960768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas.
    Adeniran AJ; Zhu Z; Gandhi M; Steward DL; Fidler JP; Giordano TJ; Biddinger PW; Nikiforov YE
    Am J Surg Pathol; 2006 Feb; 30(2):216-22. PubMed ID: 16434896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan.
    Yamazaki H; Kunisaki C; Sugimori M; Rino Y; Saito A
    Endocrine; 2024 Aug; 85(2):766-776. PubMed ID: 38407696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nodal Metastases Associated With Fusion Oncogenes Are Age Dependent in Young Adult Patients With Thyroid Cancer.
    Li H; Han R; Meng L; Sun Y; Zhao M; Zhou W; Xie J; Yu D; Shen L; Zhou Y; Wang S; Yan J; Wang W; Ye L
    J Clin Endocrinol Metab; 2023 Dec; 109(1):143-150. PubMed ID: 37536280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
    Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
    Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome.
    Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA
    Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568
    [No Abstract]   [Full Text] [Related]  

  • 59. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
    Barbaro D; Incensati RM; Materazzi G; Boni G; Grosso M; Panicucci E; Lapi P; Pasquini C; Miccoli P
    Endocrine; 2014 Apr; 45(3):462-8. PubMed ID: 23925579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer.
    Martínez JRW; Vargas-Salas S; Gamboa SU; Muñoz E; Domínguez JM; León A; Droppelmann N; Solar A; Zafereo M; Holsinger FC; González HE
    Horm Cancer; 2019 Jun; 10(2-3):97-106. PubMed ID: 30903583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.